

Supplementary Table S3: Summary of abemaciclib dose adjustments in the safety population of the monarchHER trial.

	Abemaciclib + Trastuzumab + Fulvestrant (Arm A) (N=78)	Abemaciclib + Trastuzumab (Arm B) (N=77)
	n (%)	
Number of patients with dose reduction	39 (50.0)	32 (41.6)
Patients with 1 dose reduction	28 (35.9)	19 (24.7)
Patients with 2 dose reductions	11 (14.1)	13 (16.9)
Patients with \geq 3 dose reductions	0 (0.0)	0 (0.0)